Real-World Insights on Switching Aflibercept Dosage for Enhanced Outcomes in Retinal Vein Occlusion (RISE-RVO): visual, anatomical and durability outcomes.

چکیده

Evaluation of durability outcomes after switching to aflibercept 8 mg for macular oedema in retinal vein occlusion (RVO). We evaluated eyes with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), switching from other anti-vascular endothelial growth factor treatments to…

متن کامل چکیده در سایت ناشر در دسترس است.

موضوعات مرتبط

• درمان های ضد VEGF
• شبکیه